Detalles de la búsqueda
1.
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Am J Hematol
; 99(4): 763-766, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38317312
2.
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
Am J Hematol
; 99(4): 759-762, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38314531
3.
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Leukemia
; 36(7): 1879-1886, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35676453
4.
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.
Leuk Lymphoma
; 62(1): 194-202, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33021423
5.
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission.
Leukemia
; 34(8): 2113-2124, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32472084
6.
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Leukemia
; 38(4): 893-897, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38472478
Resultados
1 -
6
de 6
1
Próxima >
>>